Dyadic International (NASDAQ:DYAI – Get Free Report) and Arvinas (NASDAQ:ARVN – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk and institutional ownership.
Risk and Volatility
Dyadic International has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Comparatively, Arvinas has a beta of 1.75, suggesting that its share price is 75% more volatile than the S&P 500.
Earnings & Valuation
This table compares Dyadic International and Arvinas”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Dyadic International | $3.09 million | 5.39 | -$7.36 million | ($0.23) | -1.81 |
| Arvinas | $262.60 million | 1.86 | -$80.80 million | $0.10 | 75.90 |
Dyadic International has higher earnings, but lower revenue than Arvinas. Dyadic International is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
27.9% of Dyadic International shares are held by institutional investors. Comparatively, 95.2% of Arvinas shares are held by institutional investors. 20.9% of Dyadic International shares are held by company insiders. Comparatively, 7.3% of Arvinas shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Dyadic International and Arvinas’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Dyadic International | -201.43% | -2,920.31% | -84.77% |
| Arvinas | 2.94% | 1.91% | 1.29% |
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Dyadic International and Arvinas, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Dyadic International | 1 | 0 | 1 | 0 | 2.00 |
| Arvinas | 2 | 3 | 5 | 0 | 2.30 |
Dyadic International presently has a consensus target price of $3.00, suggesting a potential upside of 621.15%. Arvinas has a consensus target price of $14.55, suggesting a potential upside of 91.64%. Given Dyadic International’s higher probable upside, analysts plainly believe Dyadic International is more favorable than Arvinas.
Summary
Arvinas beats Dyadic International on 10 of the 14 factors compared between the two stocks.
About Dyadic International
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
About Arvinas
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with MarketBeat.com's FREE daily email newsletter.
